目的 分析采用美托洛尔联合通心络治疗冠心病心绞痛的效果及安全性能否优于单用美托洛尔。方法? 选取 2019 年 8 月至 2020 年 8 月日照市中医医院收治的 82 例冠心病心绞痛患者为研究对象，依据随机数字表法完成分组，即对照组和研究组，每组 41 例。所有患者均给予常规治疗，对照组在常规治疗基础上采用美托洛尔治疗，研究组在对照组基础上联合通心络治疗。两组患者均治疗 2个月后比较治疗总有效率、血脂水平及不良反应情况。结果? 研究组患者治疗总有效率 92.68%，高于对照组的 75.61%（P ＜ 0.05）；治疗前，两组患者的血脂指标水平比较，差异无统计学意义（P ＞ 0.05），治疗后，两组患者的血脂指标水平均有所改善，且研究组均优于对照组（P ＜ 0.05）；研究组患者不良反应发生率 7.32% 低于对照组的 14.63%（P ＞ 0.05）。结论? 通过美托洛尔联合通心络治疗 冠心病心绞痛的效果显著，能有效改善患者的血脂水平，且不良反应少，安全性比较高，值得在临床中推广与应用。
Objective Analyze the effect of treatment with Metoprolol combined with Tongxinluo in patients with coronary heart disease and angina pectoris，comparing the safty between two groups. Methods?A total of 82 patients with coronary heart disease and angina pectoris admitted to Rizhao Hospital of Traditional Chinese Medicine from August 2019 to August 2020 were selected as the research objects. According to the random number table method，the groups were divided into control group and study group，with 41 cases in each group. All patients received routine treatment，and the control group received Metoprolol treatment in addition to conventional treatment. The study group was treated with Metoprolol combined with Tongxinluo on the basis of the control group. After two months of treatment，the clinical efficacy，blood lipid levels and adverse reactions were compared between two groups. Results?The total effective rate of the study group was 92.68%，which was higher than that of the control group （P ＜ 0.05）. Before treatment，there was no statistical significance in the level of blood lipid indexes between two groups（P ＞ 0.05）；After treatment，the levels of blood lipid indexes in two groups were improved，and the study group was better than the control group（P ＜ 0.05）；The incidence of ADR in the study group was 7.32% lower than that in the control group 19.51%（P ＜ 0.05）. Conclusion?Metoprolol combined with Tongxinluo has a significant effect on the treatment of coronary heart disease and angina pectoris. It can effectively improve the patients’blood lipid level，with few adverse reactions. It is worthy of clinical promotion and application.